Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) EPS (Weighted Average and Diluted) (2019 - 2025)

Legend Biotech filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being $3086.4 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 97.49% to $3086.4 in Q4 2025 year-over-year; TTM through Dec 2025 was $3086.4, a 97.49% decrease, with the full-year FY2025 number at $40864.2, up 8513474.49% from a year prior.
  • EPS (Weighted Average and Diluted) hit $3086.4 in Q4 2025 for Legend Biotech, up from -$53412.5 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $122916.7 in Q4 2024 to a low of -$948228.6 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.34 (2021), compared with a mean of -$118161.4.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 78.87% in 2025, down 97.49% in 2025.
  • Legend Biotech's EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then surged by 65.28% to -$0.1 in 2022, then surged by 117514598.01% to $122916.7 in 2024, then crashed by 97.49% to $3086.4 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $3086.4 (Q4 2025), -$53412.5 (Q3 2025), and -$200348.4 (Q2 2025) per Business Quant data.